Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab in Relapsed or Refractory Hodgkin Lymphoma
NCT03120676Phase 2Terminated
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Apr 2017
- Primary completion
- Nov 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of atezolizumab in Hodgkin lymphoma (HL), sponsored by Memorial Sloan Kettering Cancer Center. Started Apr 2017; status: terminated.
02
Drugs
atezolizumab
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT03120676.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03120676.